The pattern is becoming hard to ignore. Independents with access to private credit and patient capital are outbidding studios whose acquisitions are being pre-vetted by parent-company finance teams.
The script itself is being kept tightly under wraps. People who have read it say it is "completely different" from what its writer is known for.
